** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 11.8% to $61 premarket
** Co reports Q4 revenue of $190.6 mln, beating analysts' average estimate of $175.4 mln, on strong demand for rare-disease drugs Iluvien and Yutiq - data compiled by LSEG
** Posts adj. Q4 profit of $1.63 per share vs estimates of $1.44
** Stock has fallen 8.9% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。